阿巴西普治疗类风湿关节炎。

Academic Unit of Musculoskeletal Disease, University of Leeds, Chapel Allerton Hospital Leeds, UK.

Ther Clin Risk Manag. 2006 Dec;2(4):365-75. doi: 10.2147/tcrm.2006.2.4.365.

Abatacept (CTLA4-Ig) is a new agent which targets T-cell activation, an event which is thought to be critical to the onset and maintenance of rheumatoid arthritis (RA). Abatacept now has substantial evidence from phase III trials for efficacy in patients with RA who have failed to respond to disease-modifying antirheumatic drugs (DMARDs) and antitumor necrosis factor-alpha (TNF-alpha) biologic agents. Safety profile is favorable in combination with DMARDs. The mechanism of action and available evidence of its efficacy and safety are reviewed in this article.

阿巴西普（CTLA4-Ig）是一种新型的靶向 T 细胞激活的药物，被认为是类风湿关节炎（RA）发病和持续存在的关键因素。阿巴西普在治疗对疾病修饰抗风湿药物（DMARDs）和抗肿瘤坏死因子-α（TNF-α）生物制剂反应不佳的 RA 患者的 III 期临床试验中已获得充分的疗效证据。与 DMARDs 联合使用时，安全性良好。本文对其作用机制、疗效和安全性的现有证据进行了综述。